The study is double-blind and randomized, which means the treatment is assigned by chance and neither the participants nor the study team knows who receives which treatment during the study. The study has two parts. In the first part, the focus is on safety and how well the treatment is tolerated. In the second part, the focus is on whether the treatment helps improve symptoms over time. During the study, blood samples may be taken to look at levels of certain immune proteins, called IgG, IgM, and IgA, and to check for antibodies against the study drug.

Aritinercept is described as a dual BAFF/APRIL inhibitor, meaning it blocks two signals in the immune system that can help immune cells survive and stay active. This may reduce the immune attack that contributes to symptoms in generalized myasthenia gravis.

Participants in the study will receive either the HLX10 treatment or a placebo, alongside the standard chemotherapy and radiotherapy. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the HLX10 or the placebo. This helps ensure that the results are unbiased. The study will take place over a period of time, with regular monitoring to assess the treatment’s impact on the cancer and any side effects experienced by the participants.

The main goal is to see if the combination of HLX10 with chemotherapy and radiotherapy can improve overall survival rates for patients with LS-SCLC. Secondary goals include measuring progression-free survival, which is the length of time during and after treatment that a patient lives with the disease without it getting worse, and the objective response rate, which is the proportion of patients whose cancer shrinks or disappears after treatment. The study will also monitor the quality of life of participants and any adverse events that occur during the trial.

The study is for people whose cancer has gotten worse after treatment with platinum-based chemotherapy and anti-PD-L1 or anti-PD-1 therapy, which are treatments that help the immune system fight cancer. Treatment of physician’s choice may include topotecan, tisotumab vedotin, irinotecan, pemetrexed, gemcitabine, or vinorelbine, and some medicines may be given with supportive care such as paracetamol, H2-receptor antagonists, and glucocorticoids to help reduce side effects. The study is randomized, which means treatment is assigned by chance, and it is open-label, which means both the study team and the participant know which treatment is being given.

The study has an initial part and then a larger comparison part. In the first part, MK-2870 is given to gather early information about how it acts in the body and how well it is tolerated. In the main part, MK-2870 is compared with other available cancer treatments. Treatment is given over time, with regular study visits and checks for side effects and general health while the cancer is being followed.

The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

The study is planned in two groups, and neither the participants nor the study team will know which treatment is given. After starting treatment, the medicine is taken for a period of time and then the study looks at changes in urine protein and kidney function over about 20 weeks. The study is designed to compare BI 764198 with placebo across the different kidney disease groups.

The main purpose of this research is to determine if the combination of these three medications can help patients live longer compared to using docetaxel by itself. The study involves two groups of patients – one receiving all three medications, while the other group receives only docetaxel. The medications are given through different methods: tislelizumab and docetaxel are given through an intravenous infusion (into a vein), while N-803 is given as a subcutaneous injection (under the skin).

During the study, patients will receive treatment and have regular check-ups to monitor their health and how well the treatment is working. The treatment will continue as long as it appears to be helping and the side effects are manageable. Doctors will use special scanning techniques to measure if the tumors are shrinking and will track how long patients live after starting the treatment.

The purpose of the study is to demonstrate that the N‑AVD regimen is not worse than the BrECADD regimen in achieving a complete metabolic response, which is evaluated using PET/CT imaging about six to eight weeks after the chemotherapy is finished.

Participants receive the assigned drugs by infusion or injection every three weeks for a series of treatment cycles. After the final cycle, a PET/CT scan checks whether the cancer has disappeared. Follow‑up visits continue for several years to monitor overall survival, disease‑free time, quality of life, and any side effects, with occasional blood tests to look for disease markers and hormone recovery.

The purpose of the study is to assess whether povetacicept is safe and well‑tolerated in adults with this disease. Participants are randomly assigned to receive either the study drug or the placebo and attend regular clinic visits over several weeks, during which they receive the assigned treatment and undergo routine health checks.

Key assessments include measuring the level of immunoglobulin G, a type of antibody that helps the immune system, to see how it changes during treatment, and monitoring for any side effects or serious health problems. All observations are recorded to determine the overall safety profile of the medication.

People in the study are assigned by chance to receive different doses of ELV001 or placebo tablets. The study is double-blind, which means that the treatment given is not known to the participants or the study team during the study. Treatment is taken for a period of time, and the health of the joints and overall condition are checked during the study visits. Safety is also watched closely, including possible side effects and changes in heart tracing, blood tests, and vital signs.

The study is looking at whether ELV001 can improve signs and symptoms of active rheumatoid arthritis when added to standard treatment. It also compares different dose levels to see how they work and how well they are tolerated.

People in the study are assigned by chance to receive different doses of JNJ-95597528 or placebo, and neither the participants nor the study team know which treatment is given during the study. Treatment is given over a period of time, and the skin condition is followed during the study visits. The study is designed to learn whether this medicine may help reduce the signs and symptoms of Atopic Dermatitis.

People in the study are assigned by chance to receive either orelabrutinib or placebo. The study is set up so that neither the participants nor the study doctors know which treatment is being given during the trial. Treatment is taken over time, and the study follows participants to see how their condition changes during the study period.

PPMS can affect walking, balance, hand use, and other body functions. Disability progression means a gradual increase in these problems. The study is designed to compare how often this worsening happens in the two groups.

The purpose of the study is to see how well JNJ-79635322 works in people with this form of multiple myeloma. The study is open-label, which means everyone in the study receives the same treatment and knows what it is. Participants will receive the study medicine and be followed over time while the study team checks how the disease responds and watches for side effects.

This study is for people who have already had several previous treatments, including a PI, an IMiD, and an anti-CD38 antibody. A PI is a medicine that blocks a protein used by cancer cells to grow, an IMiD is a medicine that helps the immune system fight cancer, and an anti-CD38 antibody is a medicine that targets a protein on myeloma cells.

This clinical trial is focused on studying treatments for Stage IV non-small cell lung cancer (NSCLC), a type of lung cancer that has spread to other parts of the body. The study will explore the effectiveness and safety of different treatment combinations. One of the main treatments being tested is pembrolizumab, also known by its code name MK-3475. Pembrolizumab is a type of medication that helps the immune system fight cancer cells. Other treatments being studied in combination with pembrolizumab include patritumab deruxtecan (code name MK-1022), paclitaxel, pemetrexed disodium, carboplatin, and paclitaxel albumin-bound.

The purpose of this study is to evaluate how well these treatment combinations work and how safe they are for patients. Participants will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the participants’ response to the treatments and any side effects they may experience. The goal is to find the most effective and safe treatment options for patients with Stage IV NSCLC.

Throughout the study, researchers will assess the Objective Response Rate (ORR), which measures how well the cancer responds to the treatment. They will also track the number of participants who experience side effects and those who may need to stop the treatment due to these effects. Additionally, the study will look at the Duration of Response (DOR), Progression-Free Survival (PFS), and Overall Survival (OS) to understand the long-term benefits of the treatments. This research aims to improve treatment options for patients with advanced lung cancer.

The study is open label, which means the treatment is known and no hidden treatment is used. It is designed for people who finished a previous remibrutinib study and were thought to be doing well enough to continue treatment. During the trial, remibrutinib is taken over a longer period of time, and health is watched for any side effects, including common adverse events and more serious serious adverse events.

The study is a Phase 3 trial, which means it is being done in a larger group of people to better understand how well the treatment works and how safe it is. People taking part are assigned by chance to receive either nipocalimab or placebo. The treatment is given over time, and the study team follows participants through the treatment period to observe how the disease changes.

The study lasts about 72 weeks. People in the study are placed into different groups by chance, and neither the participants nor the study team know who receives RO7795068 or placebo during the study. Before treatment starts, a first check is done. After that, the medicine is given regularly, and follow-up visits continue through the study period to monitor weight, blood sugar, and overall health.

The study also looks at changes related to HbA1c, a blood test that shows average blood sugar over time, as well as waist size, blood pressure, cholesterol, and possible side effects. It also checks how the treatment may affect daily physical function and quality of life.

People in the study are assigned by chance to receive different doses of ICP-332 or placebo. The treatment is taken over a period of time, and the study team follows participants during the trial to see how the skin condition and itching change and to watch for any side effects. The medicine being tested has the code name ICP-332 and the active substance is 3-[(3AS,6AR)-5-{5-CHLORO-2-[(1-METHYL-1H-PYRAZOL-4-YL)AMINO]PYRIMIDIN-4-YL}-3A-METHYLHEXAHYDROPYRROLO[3,4-C]PYRROL-2(1H)-YL]-3-OXOPROPANENITRILE.

The study is a long-term extension, which means it follows people over a longer period after earlier treatment. During the trial, the medicine is taken by mouth and participants are watched over time for side effects and other health changes. Regular checkups and laboratory tests are used to follow general health, joint symptoms, and skin symptoms while treatment continues.

The purpose of the study is to see if MET097 helps participants lose more weight than the placebo after about 64 weeks. Throughout the trial, participants will visit the clinic regularly for weight checks, safety assessments, and blood tests, including a measurement of HbA1c, a test that shows the average blood‑sugar level over the past two to three months. Additional evaluations will monitor changes in cholesterol, blood pressure, and overall health status, and the study will continue with follow‑up visits for up to roughly 84 weeks.

The purpose of the study is to test whether BMS-986504 combined with nab-paclitaxel and gemcitabine can help people live longer and delay the time until the cancer gets worse compared to placebo combined with nab-paclitaxel and gemcitabine. The study will also look at whether the combination treatment can shrink tumors and control tumor growth. People joining the study must have their cancer confirmed through tissue samples and must have evidence of the MTAP deletion in their tumor. The cancer must have spread to other parts of the body with at least one area that can be measured on scans.

During the study, people will be randomly assigned to receive either BMS-986504 or placebo, both given together with nab-paclitaxel and gemcitabine. The study will track how long it takes for the cancer to worsen on scans and how long people survive. Researchers will also measure how much tumors shrink, how long any shrinkage lasts, and how many people experience tumor control or shrinkage. People in the study must not have received any cancer treatment for their spread disease before joining, although they may have received up to one cycle of nab-paclitaxel and gemcitabine before being assigned to a treatment group.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The purpose of this research is to determine how well IMVT-1402 works compared to placebo in treating adults with Graves’ Disease. The study examines the medication’s effects on thyroid hormone levels and the need for standard thyroid medications over a 26-week period.

During the study, participants will receive either IMVT-1402 injections or placebo. The medication will be given as a subcutaneous injection, which means it is administered under the skin. The maximum daily dose of the study medication can be up to 600 milligrams. The study will monitor how the treatment affects thyroid hormone levels and overall thyroid function throughout the treatment period.

The medications being tested contain active substances called trospium chloride and xanomeline tartrate. They come in the form of capsules that are taken by mouth. The study will involve patients who have previously participated in related research studies of these medications.

During the study, researchers will monitor various aspects of participants’ health, including any side effects, changes in body weight, blood pressure, heart rate, and mental function. They will also check for any unusual movements, restlessness, and other health-related factors to ensure the medications’ safety over extended use.

The study will compare two different doses of CIT-013 (50 mg and 100 mg) against a placebo to determine how well the medication works in treating the symptoms of Hidradenitis Suppurativa. The purpose is to evaluate if CIT-013 can effectively reduce disease activity in people with this condition.

During the study, participants will receive multiple doses of either CIT-013 or placebo over several weeks. The treatment will be administered as a concentrate that is prepared as a solution for injection. The study will monitor various aspects of the disease, including changes in the number of skin lesions, pain levels, and overall quality of life for the participants.